Adlai Nortye is a global clinical-stage biotechnology company focused on innovative oncology drugs, with its R&D and global clinical operation centers in the U.S. and China. The Company has built a global pipeline through collaborations and internal discovery with six drug candidates. Three candidates in clinical development include (i) Buparlisib (AN2025), a pan-PI3K inhibitor, currently in a global Phase III clinical trial, (ii) Palupiprant (AN0025), an oral EP4 antagonist, is in Phase 1b trials in combination with pembrolizumab in patients with multiple solid tumors; and (iii) AN4005, an oral small molecule PD-L1 drug, is currently in Phase I trials. In addition, a Phase I clinical trial has been initiated for AN2025, AN0025, and atezolizumab combination therapy to treat a variety of solid tumors bearing PIK3CA mutations. We also continue to advance in-house three preclinical programs, which include: AN8025, a multifunctional antibody as T cell and antigen-presenting cell (APC) modulator fusion protein; AN1025, an oral small molecule degrader of β-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor.